86902-27-4Relevant articles and documents
NOVEL GLUCOCORTICOID RECEPTOR AGONISTS
-
Page/Page column 49-50, (2010/12/26)
This invention relates to novel glucocorticoid receptor agonists of formula (I) and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to their combination with one or more other therapeutic agents, as well as to their use for the treatment of a number of inflammatory and allergic diseases, disorders and conditions.
FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS
-
Page 227, (2008/06/13)
The invention relates to compounds of the formulae (I) to (III) wherein the substituents are as defined in the specification. These compounds have kinase inhibitory activity, such as VEGFR/KDR inhibitory activity. Accordingly, the compounds of the formulae (I) to (III) would be useful in the prevention and treatment of angiogenesis related disorders, ophthalmological conditions, proliferative diseases, inflammatory diseases, and other pathological conditions as described in the specification.
β1-Selective Adrenoceptor Antagonists. 2. 4-Ether-Linked Phenoxypropanolamines
Machin, Peter J.,Hurst, David N.,Bradshaw, Rachel M.,Blaber, Leslie C.,Burden, David T.,et al.
, p. 1570 - 1576 (2007/10/02)
A series of 4-substituted phenoxypropanolamines was prepared and examined for β-adrenoceptor activity.Some of the compounds, especially the oxy>ethoxy>phenoxy>propanolamines (14, 15, and 24), showed potent β1-blo